Marinomed Biotech AG

Marinomed is a biopharmaceutical company specialized on innovative products based on the patent protected technology platforms Marinosolv® and the Carragelose®. The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds with the lead product Budesolv having successfully completed a pivotal Phase III study. The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract including SARS-CoV-2.

R&D:Extension of Carragelose® for prevention and treatment of SARS-CoV-2 infection. Clinical data underscore the protection Carragelose can provide against a number of different viruses, including COVID-19. Marinomed revolutionises drug development by improving the bioavailibility and efficacy of drugs with Marinosolv®. By removing the solubility barrier, Marinomed increases efficacy, time to action and safety.

Production:The products are manufactured by various providers in western Europe on behalf of Marinomed. Its sales partners, most of which are well-known pharmaceutical firms, obtain licenses from Marinomed to sell its products for individual geographical regions.

Services:Marinomed offers its patented Marinosolv technology to customers in all stages of pharmaceutical devopement. Marinosolv makes normally insoluble compounds dissolve, which means they are more readily available for the body to absorb. Please contact us for further information.